Table I.

Patient characteristics of 60 patients with locoregional disease after chemoradiation.

Variables	Number	Percentage (%)
Gender
Male	51	85
Female	9	15
T-stage (prior to chemoradiation)
T2	3	5
T3	30	50
T4	27	45
N-stage (prior to chemoradiation)
N0	15	25
N1	7	12
N2a	3	5
N2b	13	22
N2c	17	28
N3	5	8
Primary site
Hypopharynx	35	58
Larynx	25	42
Operability
Unresectable	4	7
Organ preservation approach	56	93
Chemoradiation schedule
Cisplatin IA*	2	3
Cisplatin IV*	24	40
Cisplatin/5-FU alternating**	14	24
Cisplatin/5-FU sequential ***	13	22
Cetuximab****	5	8
Cetuximab/TPF/Cisplatin or carboplatin*****	2	3

^*Concurrent four intra-arterial cisplatin (150 mg/m²) infusions or three intravenous cisplatin (100 mg/m²) infusions. In both schemes patients were radiatedwith 70 Gy irradiation (6-7 weeks);

^**cisplatin 20 mg/kg and 5-FU 200 mg/kg intravenously in week 1, 4, 7, 10; radiotherapy in week 2, 3, 5, 6, 8, 9, total dose 60 Gy;

^***cisplatin 100 mg/kg and 5-FU 1000 mg/kg intravenously, 4 courses; followed by 7 weeks radiotherapy, total dose 70 Gy;

^****weekly cetuximab in combination with 7 weeks radiotherapy, total dose 70 Gy;

^*****2-4 courses of TPF (Docetaxel, Platinum, Fluorouracil), followed by cisplatin or carboplatin with concurrent 70 Gy radiotherapy (7 weeks), in some patients cetuximab was given during this treatment.